{"id":108,"date":"2014-02-21T00:26:58","date_gmt":"2014-02-21T00:26:58","guid":{"rendered":"http:\/\/ibtherapeutics.com\/?page_id=108"},"modified":"2017-09-19T11:36:59","modified_gmt":"2017-09-19T09:36:59","slug":"board-of-directors","status":"publish","type":"page","link":"https:\/\/ibtherapeutics.com\/sv\/om-ibt\/board-of-directors\/","title":{"rendered":"Styrelse"},"content":{"rendered":"<div class=\"members cf\"><div class=\"member cf\"><img src=\"https:\/\/ibtherapeutics.com\/sv\/wp-content\/uploads\/2015\/11\/peter_rothschild.jpg\" class=\"picture\" alt=\"Peter Rothschild\" \/><h2>Peter Rothschild<\/h2><h3>Styrelseordf\u00f6rande sedan 2011. F\u00f6dd 1950.<\/h3>Civilekonomexamen fr\u00e5n Handelsh\u00f6gskolan i Stockholm.<br \/>\r\n<br \/>\r\nStyrelseordf\u00f6rande i Annwall & Rothschild Investments AB och styrelseledamot i Allbright. <br \/>\r\nGrundare och tidigare VD och styrelseordf\u00f6rande f\u00f6r BioGaia AB (publ) och styrelseledamot i Moberg Pharma AB (publ).<br \/>\r\n<br \/>\r\nAktie\u00e4gande i Bolaget: 453 283 A-aktier och 721 351 B-aktier genom Annwall & Rothschild Investments AB, ett bolag som \u00e4gs tillsammans med Jan Annwall.<\/div><div class=\"member cf\"><img src=\"https:\/\/ibtherapeutics.com\/sv\/wp-content\/uploads\/2015\/11\/Margareta2-e1706607842452.jpg\" class=\"picture\" alt=\"Margareta Hagman\" \/><h2>Margareta Hagman<\/h2><h3>Styrelseledamot sedan 2015. F\u00f6dd 1966.<\/h3>Civilekonom, \u00d6rebro universitet.<br \/>\r\n<br \/>\r\nSedan augusti 2024 CFO p\u00e5 Isofol Medical AB.<br \/>\r\n<br \/>\r\nTidigare befattningar: Finanschef och Vice VD f\u00f6r BioGaia AB (publ). \u00c4ven varit verksam som r\u00e5dgivare och konsult inom Ekonomi, Redovisning och Finans med bland annat interimsuppdrag som CFO p\u00e5 Xbrane BioPharma AB och Ortivus AB.<br \/>\r\n<br \/>\r\nAktie\u00e4gande i Bolaget: 5 284 B-aktier.<br \/>\r\n<\/div><div class=\"member cf\"><img src=\"https:\/\/ibtherapeutics.com\/sv\/wp-content\/uploads\/2017\/06\/Anthon-Jahreskog-e1539249542323.jpg\" class=\"picture\" alt=\"Anthon Jahreskog\" \/><h2>Anthon Jahreskog<\/h2><h3>Styrelseledamot sedan 2017. F\u00f6dd 1980.<\/h3>Kandidatexamen i Management and systems, City University, London. Civilekonomutbildning, magisterexamen i finansiellt management vid University of Cape Town.<br \/>\r\n<br \/>\r\nStyrelseordf\u00f6rande Fast Track Technologies Sweden AB och styrelseledamot i BioGaia AB (publ).<br \/>\r\n<br \/>\r\nAktie\u00e4gande i Bolaget: 24 270 aktier av serie B.<\/div><div class=\"member cf\"><img src=\"https:\/\/ibtherapeutics.com\/sv\/wp-content\/uploads\/2017\/06\/Eva-Ide\u0301n-picture.jpeg\" class=\"picture\" alt=\"Eva Id\u00e9n\" \/><h2>Eva Id\u00e9n<\/h2><h3>Styrelseledamot sedan 2017. F\u00f6dd 1966.<\/h3>Civilingenj\u00f6r i kemiteknik, Chalmers tekniska h\u00f6gskola.<br \/>\r\n<br \/>\r\nVerksam som konsult inom ledarskap och organisationsutveckling och inom ramen f\u00f6r den verksamheten \u00e4gare av Better & Beyond AB och partner och styrelseordf\u00f6rande i Inflecto AB.<br \/>\r\n<br \/>\r\nTidigare befattningar: M\u00e5ng\u00e5rig erfarenhet fr\u00e5n ledande befattningar i Asta och AstraZeneca.<br \/>\r\n<br \/>\r\nAktie\u00e4gande i Bolaget: 560 B-aktier.<\/div><div class=\"member cf\"><img src=\"https:\/\/ibtherapeutics.com\/sv\/wp-content\/uploads\/2018\/05\/Kristina-2013-e1534772657182.jpeg\" class=\"picture\" alt=\"Kristina Sj\u00f6blom Nygren\" \/><h2>Kristina Sj\u00f6blom Nygren<\/h2><h3>Styrelsledamot sedan 2018. F\u00f6dd 1961<\/h3>Kristina \u00e4r legitimerad l\u00e4kare och har en MD fr\u00e5n Karolinska Institutet samt en Diploma<br \/>\r\nPharmaceutical Medicine.<br \/>\r\n<br \/>\r\nHon \u00e4r sedan maj 2021 Chief Medical Officer, Head Clinical Development p\u00e5 Egetis Therapeutics AB (publ).<br \/>\r\n<br \/>\r\nTidigare erfarenhet fr\u00e5n l\u00e4kemedelsindustrin d\u00e4r hon bland annat varit Chief Medical Officer, Head Development p\u00e5 Santhera Pharmaceuticals i Basel samt Head of Clinical Development p\u00e5 SOBI.<br \/>\r\n<br \/>\r\nAktie\u00e4gande i bolaget: 100 aktier av serie B.<br \/>\r\n<br \/>\r\n<br \/>\r\n<br \/>\r\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":408,"menu_order":16,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/pages\/108"}],"collection":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/comments?post=108"}],"version-history":[{"count":37,"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/pages\/108\/revisions"}],"predecessor-version":[{"id":1591,"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/pages\/108\/revisions\/1591"}],"up":[{"embeddable":true,"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/pages\/408"}],"wp:attachment":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}